Explore 3 Stock Ideas & Industry Insights Download Free Report

Globus Medical

Healthcare US GMED

80.04USD
0.85(1.07%)

Last update at 2026-06-23T20:00:00Z

Day Range

78.9280.63
LowHigh

52 Week Range

51.79101.40
LowHigh

Fundamentals

  • Previous Close 79.19
  • Market Cap12690.79M
  • Volume1673418
  • P/E Ratio23.94
  • Dividend Yield-%
  • EBITDA877.11M
  • Revenue TTM2938.93M
  • Revenue Per Share TTM21.73
  • Gross Profit TTM 2000.58M
  • Diluted EPS TTM3.92

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 609.90M 120.72M 165.39M 243.02M 180.41M
Minority interest - - - - -
Net income 537.90M 102.98M 122.87M 190.17M 149.19M
Selling general administrative 1178.50M 981.05M 643.41M 432.12M 408.15M
Selling and marketing expenses - - - - -
Gross profit 1981.10M 1483.88M 1020.30M 759.12M 718.88M
Reconciled depreciation 276.84M 254.02M 144.73M 68.25M 69.87M
Ebit 609.90M 219.70M 201.85M 227.95M 171.95M
Ebitda 729.90M 473.73M 346.58M 313.82M 289.05M
Depreciation and amortization 120.00M 254.02M 144.73M 85.87M 117.10M
Non operating income net other - - - 15.07M 8.45M
Operating income 479.80M 165.99M 133.14M 227.95M 171.95M
Other operating expenses 2459.10M 2353.36M 1435.33M 786.59M 763.24M
Interest expense - 4.19M 20.13M 14.23M 9.30M
Tax provision 67.20M 17.74M 42.52M 52.85M 31.22M
Interest income - - - - -
Net interest income 7.14M -4.18900M 20.13M 14.23M 9.30M
Extraordinary items - - - - -
Non recurring - - - 8.30M 22.91M
Other items - - - - -
Income tax expense 72.00M 17.74M 42.52M 52.85M 31.22M
Total revenue 2938.90M 2519.36M 1568.48M 1022.84M 958.10M
Total operating expenses 1501.30M 1317.88M 887.16M 522.87M 524.02M
Cost of revenue 957.80M 1035.48M 548.17M 263.73M 239.22M
Total other income expense net 130.10M -45.26900M 32.25M 15.07M 8.45M
Discontinued operations - - - - -
Net income from continuing ops 537.87M 102.98M 122.87M 190.17M 149.19M
Net income applicable to common shares - - - 190.17M 149.19M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5302.76M 5251.75M 5086.08M 2076.13M 1957.26M
Intangible assets 745.06M 795.12M 924.60M 63.57M 68.66M
Earning assets - - - - -
Other current assets 130.15M 49.64M 44.58M 21.00M 18.42M
Total liab 729.51M 1074.42M 1088.12M 229.75M 215.88M
Total stockholder equity 4573.25M 4177.33M 3997.96M 1846.37M 1741.39M
Deferred long term liab - - - 1.78M 4.31M
Other current liab 353.10M 260.24M 277.77M 109.00M 11.77M
Common stock 0.14M 0.14M 0.14M 0.10M 0.10M
Capital stock 0.14M 0.14M 0.14M 0.10M 0.10M
Retained earnings 1387.96M 1152.81M 1137.27M 1239.95M 1194.27M
Other liab - - - 70.55M 75.71M
Good will 1435.03M 1432.39M 1434.54M 197.47M 179.71M
Other assets - - - 92.16M 60.83M
Cash 526.16M 784.44M 467.29M 150.47M 193.07M
Cash and equivalents - - - - -
Total current liabilities 498.50M 855.91M 392.35M 159.20M 140.16M
Current deferred revenue 27.66M 22.14M 18.37M 14.10M 12.03M
Net debt -407.50000M -247.25000M 53.11M -150.46600M -193.06900M
Short term debt 14.74M 453.60M 11.97M - 94.41M
Short long term debt - 443.35M - - -
Short long term debt total 118.66M 537.19M 520.40M - -
Other stockholder equity 3169.81M 3031.24M 2870.75M 630.95M 553.79M
Property plant equipment - - - 243.73M 221.08M
Total current assets 2125.61M 2177.26M 1915.37M 983.34M 864.52M
Long term investments 71.82M 66.13M 75.43M 495.85M 562.48M
Net tangible assets - - - 1585.33M 1493.02M
Short term investments 31.09M 105.62M 50.50M 295.59M 250.38M
Net receivables 678.94M 578.33M 504.87M 217.31M 165.65M
Long term debt - - 417.40M - -
Inventory 759.28M 659.23M 848.13M 298.98M 237.00M
Accounts payable 98.85M 75.12M 56.67M 36.10M 21.95M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 15.35M -6.86100M -10.19200M -24.63000M -6.77200M
Additional paid in capital - - - - -
Common stock total equity - - - 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 1239.95M 1194.27M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 150.60M 75.10M 78.59M 43.31M 36.33M
Deferred long term asset charges - - - - -
Non current assets total 3177.15M 3074.49M 3170.71M 1092.78M 1092.75M
Capital lease obligations 118.66M 93.84M 103.00M - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 71.96M -176.05100M -78.13100M -4.88000M -284.55300M
Change to liabilities - - - 17.62M 26.79M
Total cashflows from investing activities -355.01400M -176.05100M 302.97M -110.36200M -375.93900M
Net borrowings -449.98500M 0.00000M 0.00000M - -
Total cash from financing activities -679.16000M -27.69600M -231.82100M -109.96200M 54.15M
Change to operating activities - - - -4.20500M 11.72M
Net income 537.87M 102.98M 122.87M 190.17M 149.19M
Change in cash -258.28200M 317.15M 316.83M -42.60300M -46.32800M
Begin period cash flow 784.44M 467.29M 150.47M 193.07M 239.40M
End period cash flow 526.16M 784.44M 467.29M 150.47M 193.07M
Total cash from operating activities 753.45M 520.64M 243.50M 178.47M 276.27M
Issuance of capital stock - - - - 63.50M
Depreciation 276.84M 254.02M 144.73M 68.25M 69.87M
Other cashflows from investing activities -275.75400M -44.15600M - -31.43500M -34.48800M
Dividends paid - - - - -
Change to inventory -17.59800M -29.86000M -70.32800M -61.74500M -11.97100M
Change to account receivables -52.18200M -78.06200M -49.91400M -50.84300M -25.89500M
Sale purchase of stock -300.45100M -85.78700M -225.56200M -144.49300M 63.50M
Other cashflows from financing activities -378.70900M 58.09M -6.25900M -7.18500M -9.34900M
Change to netincome - - - 22.57M 71.90M
Capital expenditures 164.68M 115.43M 78.27M 74.05M 56.90M
Change receivables - - - -50.84300M -25.89500M
Cash flows other operating - - - -12.93900M -6.38800M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -41.85600M -45.51800M
Change in working capital -82.71200M -97.55400M -116.59800M -105.26200M -17.25200M
Stock based compensation 49.78M 54.19M 52.74M 32.81M 30.59M
Other non cash items -46.95500M 332.89M 97.54M 14.72M 61.50M
Free cash flow 588.77M 405.21M 165.22M 104.42M 219.38M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GMED
Globus Medical
0.85 1.07% 80.04 23.94 21.69 4.32 2.86 5.05 18.22
ABT
Abbott Laboratories
2.70 3.07% 90.53 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation
5.31 1.74% 310.00 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
1.36 1.72% 80.63 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
1.27 2.86% 45.60 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

Profile

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Globus Medical

2560 General Armistead Avenue, Audubon, PA, United States, 19403-5214

Key Executives

Name Title Year Born
Mr. David C. Paul Co-Founder & Exec. Chairman 1967
Mr. Daniel T. Scavilla Pres, CEO & Director 1965
Mr. Keith W. Pfeil Sr. VP & CFO 1979
Ms. Kelly G. Huller Esq. Sr. VP, Gen. Counsel & Sec. 1972
Mr. Brian J. Kearns Sr. VP of Bus. Devel. & Investor Relations 1967
Mr. A. Brett Murphy Exec. VP of International Sales 1965
Mr. Steven M. Payne VP & Controller 1971
Mr. Mike Reeder Exec. Officer NA
Mr. Richard Holifield Exec. Officer NA
Mr. John Dowling Exec. Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.